We thank the editors for the opportunity to respond to the comment made by Balkau et al. (1) on our recent article (2).
Balkau et al. (1) were interested in detailed information about HbA1c in the overall group stratified by registry. As stated in the text, HbA1c was similar between the two registries. In the T1D Exchange Registry (TIDX), HbA1c was 8.6% (SE 0.06) in current smokers, 8.0% (0.05) in former smokers, and 7.9% (0.05) in never-smokers (P < 0.001). In the Prospective Diabetes Follow-up Registry (DPV), HbA1c was 8.5% (0.07) in current smokers, 8.2% (0.08) in former smokers, and 7.8% (0.06) in never-smokers (P < 0.001). The findings by Soulimane et al. (3) in a population without diabetes are of interest to the field as we try to better understand the best markers of glycemia. However, HbA1c is currently the best standardized and internationally comparable measurement of metabolic control in patients with diabetes. Our data describe significant differences in mean HbA1c between current smokers and never-smokers (8.5% and 7.9%, respectively, or a difference of 0.6%) in patients with type 1 diabetes versus a 0.1% difference in subjects who were not treated with glucose-lowering agents, as reported in the meta-analysis by Soulimane et al. (3). Further studies are required to investigate mechanistic explanations of whether this difference is due to nicotine, red blood cell turnover, or other physiological factors or to smoking-associated behavioral influences on metabolic control. The observation of significantly higher HbA1c levels in smokers is itself of concern. Data from a T1DX study investigating whether a racial difference exists in the relationship between continuous glucose monitoring glucose over 3 months and HbA1c were presented at the 2016 American Diabetes Association Scientific Sessions (4).
Article Information
Funding. This work was supported through the Leona M. and Harry B. Helmsley Charitable Trust and the German BMBF Competence Network Diabetes Mellitus (FKZ 01GI1106), which is integrated into the German Center for Diabetes Research as of January 2015.
Duality of Interest. No potential conflicts of interest relevant to this article were reported.
References
- 1.Balkau B, Soulimane S, Simon D, Herman WH. Comment on Hofer et al. International comparison of smoking and metabolic control in patients with type 1 diabetes. Diabetes Care 2016;39:e177–e178 10.2337/dc16-2000 [DOI] [PubMed] [Google Scholar]
- 2.Hofer SE, Miller K, Hermann JM, et al.; DPV Initiative; T1D Exchange Clinic Network . International comparison of smoking and metabolic control in patients with type 1 diabetes. Diabetes Care 2016;39:e177–e178 [DOI] [PubMed] [Google Scholar]
- 3.Soulimane S, Simon D, Herman WH, et al.; DETECT -2 Study Group; DESIR Study Group . HbA1c, fasting and 2-hour plasma glucose in current-, ex-, and non-smokers: a meta-analysis. Diabetologia 2014;57:30–39 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Bergenstal RM. Is there a racial difference in the mean continuous glucose monitoring glucose in relation to the HbA1c?—results and implications. Presented at the 76th Annual Meeting of the American Diabetes Association, 10–14 June 2016, New Orleans, Louisiana [Google Scholar]